

# SEQUENCE LISTING

<110> OKU, TADATAKE  
NISHIO, TOSHIYUKI  
KAWACHI, RYU  
SURUGA, KOHEI

<120> NOVEL HEME PEPTIDE

<130> N0008.0001

<140> 10/507,156

<141> 2004-09-07

<150> PCT/JP03/02394

<151> 2003-02-28

<150> JP 2002-058086

<151> 2002-03-04

<160> 18

<170> PatentIn Ver. 3.2

<210> 1

<211> 104

<212> PRT

<213> Equus caballus

<400> 1

Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Val Gln Lys Cys Ala Gln  
1 5 10 15

Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr Gly Pro Asn Leu  
20 25 30

His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro Gly Phe Thr Tyr  
35 40 45

Thr Asp Ala Asn Lys Asn Lys Gly Ile Thr Trp Lys Glu Glu Thr Leu  
50 55 60

Met Glu Tyr Leu Glu Asn Pro Lys Lys Tyr Ile Pro Gly Thr Lys Met  
65 70 75 80

Ile Phe Ala Gly Ile Lys Lys Lys Thr Glu Arg Glu Asp Leu Ile Ala  
85 90 95

Tyr Leu Lys Lys Ala Thr Asn Glu  
100

<210> 2

<211> 85

<212> PRT

<213> Porphyra yezoensis

<400> 2

Ala Asp Leu Asp Asn Gly Glu Lys Val Phe Ser Ala Asn Cys Ala Ala  
1 5 10 15

Cys His Ala Gly Gly Asn Asn Ala Ile Met Pro Asp Lys Thr Leu Lys  
20 25 30

Lys Asp Val Leu Glu Ala Asn Ser Met Asn Thr Ile Asp Ala Ile Thr

35                      40                      45  
 Tyr Gln Val Gln Asn Gly Lys Asn Ala Met Pro Ala Phe Gly Gly Arg  
     50                      55                      60  
 Leu Val Asp Glu Asp Ile Glu Asp Ala Ala Asn Tyr Val Leu Ser Gln  
     65                      70                      75                      80  
 Ser Glu Lys Gly Trp  
                             85

<210> 3  
 <211> 15  
 <212> PRT  
 <213> *Porphyra yezoensis*

<400> 3  
 Phe Ser Ala Asn Cys Ala Ala Cys His Ala Gly Gly Asn Asn Ala  
     1                      5                      10                      15

<210> 4  
 <211> 9  
 <212> PRT  
 <213> *Equus caballus*

<400> 4  
 Cys Ala Gln Cys His Thr Val Glu Lys  
     1                      5

<210> 5  
 <211> 22  
 <212> PRT  
 <213> *Equus caballus*

<400> 5  
 Val Gln Lys Cys Ala Gln Cys His Thr Val Glu Lys Gly Gly Lys His  
     1                      5                      10                      15

Lys Thr Gly Pro Asn Leu  
                             20

<210> 6  
 <211> 65  
 <212> PRT  
 <213> *Equus caballus*

<400> 6  
 Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Val Gln Lys Cys Ala Gln  
     1                      5                      10                      15

Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr Gly Pro Asn Leu  
                             20                      25                      30

His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro Gly Phe Thr Tyr  
                             35                      40                      45

Thr Asp Ala Asn Lys Asn Lys Gly Ile Thr Trp Lys Glu Glu Thr Leu  
     50                      55                      60

Met  
     65

<210> 7  
<211> 9  
<212> PRT  
<213> Equus caballus

<400> 7  
Cys Ala Gln Cys His Thr Val Glu Lys  
1 5

<210> 8  
<211> 21  
<212> PRT  
<213> Porphyra yezoensis

<400> 8  
Val Phe Ser Ala Asn Cys Ala Ala Cys His Ala Gly Gly Asn Asn Ala  
1 5 10 15  
Ile Met Pro Asp Lys  
20

<210> 9  
<211> 17  
<212> PRT  
<213> Equus caballus

<400> 9  
Lys Gly Lys Lys Ile Phe Val Gln Lys Cys Ala Gln Cys His Thr Val  
1 5 10 15  
Glu

<210> 10  
<211> 29  
<212> PRT  
<213> Porphyra yezoensis

<400> 10  
Val Phe Ser Ala Asn Cys Ala Ala Cys His Ala Gly Gly Asn Asn Ala  
1 5 10 15  
Ile Met Pro Asp Lys Thr Leu Lys Lys Asp Val Leu Glu  
20 25

<210> 11  
<211> 75  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Formula  
peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(20)  
<223> this region may encompass a hydrogen atom or 1-20 variable  
amino acids

<220>  
<221> MISC\_FEATURE  
<222> (22)..(23)  
<223> any amino acid

<220>  
<221> MISC\_FEATURE  
<222> (25)  
<223> His, Lys or Arg

<220>  
<221> MISC\_FEATURE  
<222> (26)..(75)  
<223> this region may encompass a hydroxyl group or 1-50 variable amino acids

<220>  
<223> see specification as filed for detailed description of preferred embodiments

<400> 11  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10 15  
Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
20 25 30  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
35 40 45  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
50 55 60  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
65 70 75

<210> 12  
<211> 75  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Formula peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(20)  
<223> this region may encompass a hydrogen atom or 1-20 variable amino acids

<220>  
<221> MISC\_FEATURE  
<222> (22)..(23)  
<223> Ala, Gln, Lys, Arg or Val

<220>  
<221> MISC\_FEATURE  
<222> (25)  
<223> His, Lys or Arg

<220>  
<221> MISC\_FEATURE  
<222> (26)..(75)  
<223> this region may encompass a hydroxyl group or 1-50 variable



Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
65 70 75

<210> 14  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 14  
Thr Val Glu Lys

<210> 15  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 15  
Phe Ser Ala Asn  
1

<210> 16  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 16  
Ala Gly Gly Asn Asn Ala  
1 5

<210> 17  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(3)  
<223> this region may encompass a hydrogen atom

<400> 17  
Val Glu Lys Cys Ala Glu Cys His Thr Val Glu  
1 5 10

<210> 18

<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 18  
Thr Val Glu Lys Gly Gly Lys His Lys Thr Gly Pro Asn Leu  
1 5 10